Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: Accidental underdose, Fatigue, Inappropriate schedule of product administration, Pyrexia, Vaccination complication
Clinical narrative: "Typical bad reactions"; Low grade fever; General fatigue; Received 50mcg IM injection (Half dose); 3rd dose received after 28 days of second dose; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION ("Typical bad reactions"), PYREXIA (Low grade fever), FATIGUE (General fatigue), ACCIDENTAL UNDERDOSE (Received 50mcg IM injection (Half dose)) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (3rd dose received after 28 days of second dose) in a 67-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 8520100102) for COVID-19 vaccination.     No Medical History information was reported.    On 28-Jan-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 50 microgram. On 28-Jan-2021, the patient experienced VACCINATION COMPLICATION ("Typical bad reactions"), PYREXIA (Low grade fever), FATIGUE (General fatigue), ACCIDENTAL UNDERDOSE (Received 50mcg IM injection (Half dose)) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (3rd dose received after 28 days of second dose). On 28-Jan-2021, ACCIDENTAL UNDERDOSE (Received 50mcg IM injection (Half dose)) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (3rd dose received after 28 days of second dose) had resolved. On 29-Jan-2021, VACCINATION COMPLICATION ("Typical bad reactions"), PYREXIA (Low grade fever) and FATIGUE (General fatigue) had resolved.            The consumer reported that he received a third booster dose, 50 mcg, of Moderna vaccine on 28Jan2021 and experienced the typical bad reactions, including low grade fever and general fatigue. He reported that the events lasted for 24 hours and resolved.  No concomitant product use was provided by the reporter.   No treatment medications were reported.  The consumer stated that he was in the Moderna COVID-19 Phase 2 Clinical Trials.  He stated that he was unblinded and did receive the actual Moderna COVID-19 vaccine and not the placebo. He stated that he received the first Moderna COVID-19 dose on 26 June 2020.  He also stated that the intramuscular injection of dose 100 mcg was given into his left deltoid and lot number was 8520100102.  The consumer stated he didn't experienced any adverse events after the first dose.   The consumer reported that he received the second Moderna COVID-19 dose on 29 July 2021. He stated that he was given 100 mcg dose into the left deltoid, intramuscularly, and lot number was 8520100103. The consumer reported that after the second dose he experienced the typical bad reactions, including low grade fever and general fatigue.  The consumer reported that the events lasted for 24 hours and resolved.    The consumer reported that he was perfectly healthy and does not use any medications daily. He also stated that he probably gave blood 12 times during the clinical trial.   Most recent FOLLOW-UP information incorporated above includes: On 26-Aug-2021: Follow up received includes added Patient's race,  Second dose start date.